AlphaCrest Capital Management’s Boston Scientific BSX Stock Holding History

AlphaCrest Capital Management’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-14,449	Closed	-$560K	–	171
2022 Q3	$560K	Buy	14,449 +3,085	+27%	+$124K	0.03%	931
2022 Q2	$424K	Sell	11,364 -6,838	-38%	-$278K	0.02%	1006
2022 Q1	$806K	Sell	18,202 -17,325	-49%	-$751K	0.05%	649
2021 Q4	$1.51M	Buy	35,527 +4,448	+14%	+$187K	0.06%	592
2021 Q3	$1.35M	Sell	31,079 -34,255	-52%	-$1.52M	0.07%	480
2021 Q2	$2.79M	Sell	65,334 -11,784	-15%	-$496K	0.12%	240
2021 Q1	$2.98M	Sell	77,118 -24,789	-24%	-$938K	0.17%	147
2020 Q4	$3.66M	Buy	101,907 +11,408	+13%	+$411K	0.3%	61
2020 Q3	$3.46M	Buy	90,499 +72,869	+413%	+$2.81M	0.38%	24
2020 Q2	$619K	Sell	17,630 -12,723	-42%	-$458K	0.1%	305
2020 Q1	$990K	Buy	+30,353	New	+$1.19M	0.12%	279
2019 Q4	–	Sell	-28,430	Closed	-$1.16M	–	1253
2019 Q3	$1.16M	Buy	+28,430	New	+$1.2M	0.07%	489
2019 Q2	–	Sell	-53,972	Closed	-$2.07M	–	1024
2019 Q1	$2.07M	Buy	+53,972	New	+$2.06M	0.31%	48

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bollard Group Boston, Massachusetts $3.39B AUM 1.06% 1-Year Est. Return

AlphaCrest Capital Management's BSX Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Boston Scientific (BSX) in Q4 2022, closing a stake of 14,449 shares — an estimated $560K sold.

AlphaCrest Capital Management first reported a position in BSX in Q1 2019 and held it in 13 quarters. The position peaked at $3.66M in Q4 2020. 929 funds tracked by Wall St. Rank hold BSX as of Q4 2022.

AlphaCrest Capital Management reported no remaining Boston Scientific position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 14,449 Boston Scientific shares in Q4 2022, an estimated $560K.
AlphaCrest Capital Management first reported a position in Boston Scientific in Q1 2019 and held it in 13 quarters.
AlphaCrest Capital Management's Boston Scientific position peaked at $3.66M in Q4 2020.
929 funds tracked by Wall St. Rank held Boston Scientific as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.